Ozempic vs. Mounjaro | A Comparison
Mounjaro and Ozempic are both FDA-approved injectable medications used to treat type 2 diabetes and chronic weight management in adults. They both belong to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a naturally occurring hormone that helps to regulate blood sugar levels and appetite.
- Both Mounjaro (Tirzepatide) and Ozempic (Semaglutide) are once-weekly injections.
- Both medications are effective at lowering blood sugar levels and promoting weight loss.
- Both medications have similar side effects, such as nausea, vomiting, diarrhea, and abdominal pain.
- Both medications are expensive, but there are payment plans and discounts available for patients who qualify.
- Mounjaro is a dual-acting GLP-1 and GIP receptor agonist, while Ozempic is a GLP-1 receptor agonist only. GIP is another naturally occurring hormone that helps to regulate blood sugar levels.
- In clinical trials, Mounjaro was more effective than Ozempic for both blood sugar control and weight loss.
Mounjaro is slightly more expensive than Ozempic.
- Mounjaro may have additional side effects, such as hypoglycemia (low blood sugar) and thyroid cancer.
Mounjaro and Ozempic (Semaglutide) are both effective medications for treating type 2 diabetes and promoting weight loss. However, Mounjaro is more effective than Ozempic for both blood sugar control and weight loss. Mounjaro is also more expensive than Semaglutide and may have additional side effects.
Which one is right for you?
If you are considering taking Mounjaro (Tirzepatide) or Ozempic (Semaglutide), it is important to talk to your doctor to discuss which medication is right for you. Your doctor will consider your individual medical history and needs when making a recommendation.